Clinical Trials · NCT06345066
A Study of LY3841136 in Overweight and Obese Participants
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 96
- Start date
- Apr 2024
- Locations
- 3 sites, United States
- Primary endpoint
- Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration